Literature DB >> 17911580

Functional human antigen-specific T cells produced in vitro using retroviral T cell receptor transfer into hematopoietic progenitors.

Anja U van Lent1, Maho Nagasawa, Marleen M van Loenen, Remko Schotte, Ton N M Schumacher, Mirjam H M Heemskerk, Hergen Spits, Nicolas Legrand.   

Abstract

In vitro production of human T cells with known Ag specificity is of major clinical interest for immunotherapy against tumors and infections. We have performed TCRalphabeta gene transfer into human hemopoietic progenitors from postnatal thymus or umbilical cord blood, and subsequently cultured these precursors on OP9 stromal cells expressing the Notch human ligand Delta-like1. We report here that fully mature, functional T cells with controlled Ag specificity are obtained from such cultures. Using vectors encoding TCRalphabeta-chains directed against melanoma (MART-1), viral (CMV), and minor histocompatibility (HA-2) Ags, we show that the obtained Ag-specific T cells exert cytolytic activity against their cognate Ag and expand in vitro upon specific TCR stimulation. Therapeutic applications may arise from these results because they provide a way to produce large numbers of autologous mature Ag-specific T cells in vitro from undifferentiated hemopoietic progenitors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17911580     DOI: 10.4049/jimmunol.179.8.4959

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

1.  Gene-modified hematopoietic stem cells for cancer immunotherapy.

Authors:  Sarah Larson; Satiro N De Oliveira
Journal:  Hum Vaccin Immunother       Date:  2014-01-09       Impact factor: 3.452

Review 2.  Next-generation stem cells - ushering in a new era of cell-based therapies.

Authors:  Erin A Kimbrel; Robert Lanza
Journal:  Nat Rev Drug Discov       Date:  2020-04-06       Impact factor: 84.694

3.  Invariant natural killer T cells generated from human adult hematopoietic stem-progenitor cells are poly-functional.

Authors:  Wenji Sun; Yi Wang; James E East; Amy S Kimball; Katherine Tkaczuk; Susan Kesmodel; Scott E Strome; Tonya J Webb
Journal:  Cytokine       Date:  2015-01-05       Impact factor: 3.861

Review 4.  Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.

Authors:  Bipulendu Jena; Gianpietro Dotti; Laurence J N Cooper
Journal:  Blood       Date:  2010-05-03       Impact factor: 22.113

Review 5.  Hematopoietic stem cells for cancer immunotherapy.

Authors:  Eric Gschweng; Satiro De Oliveira; Donald B Kohn
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

6.  Engineering antigen-specific T cells from genetically modified human hematopoietic stem cells in immunodeficient mice.

Authors:  Scott G Kitchen; Michael Bennett; Zoran Galić; Joanne Kim; Qing Xu; Alan Young; Alexis Lieberman; Aviva Joseph; Harris Goldstein; Hwee Ng; Otto Yang; Jerome A Zack
Journal:  PLoS One       Date:  2009-12-07       Impact factor: 3.240

7.  Derivation of induced pluripotent stem cells from human peripheral blood T lymphocytes.

Authors:  Matthew E Brown; Elizabeth Rondon; Deepika Rajesh; Amanda Mack; Rachel Lewis; Xuezhu Feng; Laura Jo Zitur; Randall D Learish; Emile F Nuwaysir
Journal:  PLoS One       Date:  2010-06-29       Impact factor: 3.240

Review 8.  Application of adoptive T-cell therapy using tumor antigen-specific T-cell receptor gene transfer for the treatment of human leukemia.

Authors:  Toshiki Ochi; Hiroshi Fujiwara; Masaki Yasukawa
Journal:  J Biomed Biotechnol       Date:  2010-05-05

Review 9.  Strategies to genetically engineer T cells for cancer immunotherapy.

Authors:  Timothy T Spear; Kaoru Nagato; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2016-05-02       Impact factor: 6.968

10.  TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation.

Authors:  Moniek A de Witte; Gavin M Bendle; Marly D van den Boom; Miriam Coccoris; Todd D Schell; Satvir S Tevethia; Harm van Tinteren; Elly M Mesman; Ji-Ying Song; Ton N M Schumacher
Journal:  J Immunol       Date:  2008-08-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.